International IgA Nephropathy Prediction Tool

ورودی‌های بالینی بیمار

حداقل ۱۸ — حداکثر ۶۵ • واحد: years

حداقل ۵ — حداکثر ۱۵۰ • واحد: mL/min/1.73m²

حداقل ۶۰ — حداکثر ۱۴۰ • واحد: mmHg

حداقل ۰.۰۰۱ — حداکثر ۱۵ • واحد: g/day

حداقل ۰ — حداکثر ۱ • واحد: score

حداقل ۰ — حداکثر ۱ • واحد: score

حداقل ۰ — حداکثر ۱ • واحد: score

حداقل ۰ — حداکثر ۲ • واحد: score

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
risk percentage
—%
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Very Low Risk0–10
  • Low Risk10–25
  • Moderate Risk25–50
  • High Risk50–75
Direct Clinical Answer

The International IgA Nephropathy Prediction Tool calculates predicting risk of 50% decline in eGFR or end-stage kidney disease in patients with IgA nephropathy. Key inputs include age. Scores guide adjusting renal medication clearance, coordinating nephrology follow-up, or planning renal replacement therapy. Routine clinical application promotes standardized evidence-based patient management.

Clinical Guidelines & Evidence

Predicts risk of 50% decline in eGFR or end-stage kidney disease in patients with IgA nephropathy. This validated prediction tool was developed using an international multi-ethnic cohort of 2,781 patients with biopsy-proven idiopathic IgA nephropathy. The tool uses clinical, laboratory, and histological parameters available at biopsy to provide risk estimates for kidney function decline. Two versions are available: one including race/ethnicity and one without race. The tool is endorsed by the 2021 KDIGO guidelines as the preferred method to predict kidney outcomes in IgA nephropathy patients. It facilitates clinical decision-making, patient counseling, and clinical trial enrollment by stratifying patients based on their risk of progressive kidney disease.

Clinical Indication

The International IgA Nephropathy Prediction Tool is indicated for bedside clinical practice to support Predicts risk of 50% decline in eGFR or end-stage kidney disease in patients with IgA nephropathy. This validated prediction tool was developed using an international multi-ethnic cohort of 2,781 patients with biopsy-proven idiopathic IgA nephropathy. The tool uses clinical, laboratory, and histological parameters available at biopsy to provide risk estimates for kidney function decline. Two versions are available: one including race/ethnicity and one without race. The tool is endorsed by the 2021 KDIGO guidelines as the preferred method to predict kidney outcomes in IgA nephropathy patients. It facilitates clinical decision-making, patient counseling, and clinical trial enrollment by stratifying patients based on their risk of progressive kidney disease.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with acute kidney injury (AKI), chronic kidney disease stages 1-5, or acid-base and fluid-electrolyte disturbances. Clinical application is indicated across Nephrology clinics, hemodialysis units, acute inpatient renal services, and metabolic wards.

Limitations & Contraindications

eGFR estimation equations assume steady-state serum creatinine and become unreliable during unstable AKI, amputations, or extremes of muscle mass.

Clinical Pearls & Action Plan

Serum creatinine lags behind acute reductions in glomerular filtration; monitor hourly urine output and consider cystatin C in evolving AKI. Guideline pearl: Endorsed by 2021 KDIGO guidelines as preferred method for risk prediction in IgA nephropathy.

Formula & Variables:

Risk calculation uses transformed variables: sqrt(eGFR) - 8.8, ln(urine protein + 0.26), (MAP - 100)/15, and MEST scores with specific coefficients for race-inclusive and race-free models

Input Parameters

NameTypeRequiredDescription
ageintegerYesPatient age at time of biopsy(years)
egfrfloatYesEstimated glomerular filtration rate at time of biopsy(mL/min/1.73m²)
mapfloatYesMean arterial pressure at time of biopsy(mmHg)
urine_proteinfloatYes24-hour urine protein excretion at time of biopsy(g/day)
mest_mintegerYesOxford MEST Score - Mesangial hypercellularity: M0 (≤0.5) or M1 (>0.5)(score)
mest_eintegerYesOxford MEST Score - Endocapillary hypercellularity: E0 (absent) or E1 (present)(score)
mest_sintegerYesOxford MEST Score - Segmental sclerosis: S0 (absent) or S1 (present)(score)
mest_tintegerYesOxford MEST Score - Interstitial fibrosis/tubular atrophy: T0 (0-25%), T1 (26-50%), T2 (>50%)(score)
rasb_usestringYesRenin-angiotensin system blocker use at time of biopsy
immunosuppression_usestringYesImmunosuppressive therapy use at time of biopsy
racestringNoPatient race/ethnicity (optional parameter for race-inclusive model)

Score Interpretation & Guidance

RangeStageDescription
0–10Very Low Risk5-year risk <10%
10–25Low Risk5-year risk 10-25%
25–50Moderate Risk5-year risk 25-50%
50–75High Risk5-year risk 50-75%
75–100Very High Risk5-year risk >75%

Evidence-Based References (EBM)

  • Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, et al. Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. JAMA Intern Med. 2019 Jul 1;179(7):942-952. doi: 10.1001/jamainternmed.2019.0600.DOI: 10.1001/jamainternmed.2019.0600
  • Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021 Oct;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.DOI: 10.1016/j.kint.2021.05.021
  • Zhang J, Huang B, Liu Z, Wang X, Xie M, Guo R, et al. External validation of the International IgA Nephropathy Prediction Tool. Clin J Am Soc Nephrol. 2020 Jul 7;15(7):1112-1120. doi: 10.2215/CJN.16021219.DOI: 10.2215/CJN.16021219

Related calculators